Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-04-05

FDA Approved: FASENRA — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

The FDA approved a supplemental application for FASENRA (benralizumab) from AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FASENRA (BENRALIZUMAB)

Snippet

SUPPL AP for FASENRA (BENRALIZUMAB)